




# RespiriTB announces the start of a Phase 1 clinical trial with bedaquiline long- acting injectable

Swipe for more



We are launching  
a **Phase 1 trial**  
for a long-acting  
injectable  
bedaquiline

Swipe for more



This effort is led by  
the RespiRiTB  
consortium,  
including Johnson  
& Johnson and  
Medical University  
of Vienna

Swipe for more





We aim to improve  
**TB treatment**  
**adherence and**  
**patient outcomes**

Swipe for more



**This innovative treatment has the potential to significantly reduce TB incidence and improve public health worldwide.**

